2021 Managed Healthcare Executive® Pharmacy Survey: What Federal Policy Will Most Likely Occur in 2021, Which Will Curb Drug Prices?

MHE Publication, MHE June 2021, Volume 31, Issue 6

In this final part of the MHE 2021 Pharmacy Survey, participants share their thoughts on which federal policies they favor as a way to curb drug prices and which policy is more likely to occur this year. MHE's annual pharmacy survey had over 225 respondents.

In this final part of the 2021 Pharmacy Survey slideshow series, participants shared their opinions on which federal policies they favor as a way to curb drug prices and which policy is more likely to occur this year.

The majority of respondents (23%) said requiring PBMs to reimburse pharmacies at or above pharmacies’ drug acquisition costs, is a policy they favor most as a way to curb drug prices. Other policies most favored were: restricting the use of copay accumulator programs (20%), putting limits on drug price increases (20%), negotiating Medicare drug prices (12%), putting limits on out-of-pocket costs for Medicare beneficiaries (11%), mandating transparency in coverage rules (8%), and
linking Medicare Part B drug prices to prices paid in other countries (the Most Favored Nation model) (7% ).

Related: 2021 Managed Healthcare Executive® Pharmacy Survey: Drugs New to the Market Most Likely to Reduce Morbidity, Mortality

When asked which federal policy will most likely occur in 2021, most respondents (29%) favored towards limiting on out-of-pocket costs for Medicare beneficiares. Following policies were: Most Favored Nation model for Medicare Part B drugs (23%), federal limits on drug price increase (21%), none of the above (10%), CMS negotiating Medicare drug prices (9%), and no substantial federal policy change will occur (9%).

Just over 225 people responded to our online survey between April 5 and May 10.